Aimei Health Technology Co, LTD DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Aimei Health Technology Co., Ltd. is seeking shareholder approval to extend its business combination deadline to December 2026 and reduce sponsor extension fees to facilitate its merger with United Hydrogen.
NASDAQ
Aimei Health Technology Co., Ltd. (Aimei Health) has announced a definitive business combination agreement to merge with United Hydrogen Group Inc., forming United Hydrogen Global Inc. (Pubco), a hydrogen solutions provider, in a $1.5 billion all-stock transaction.
NASDAQ
Aimei Health Technology Co., Ltd. announced the adjournment of its Extraordinary General Meeting to February 5, 2025.
NASDAQ
Aimei Health Technology is seeking shareholder approval to amend its Investment Management Trust Agreement, increasing the monthly extension fee from $0.033 per public share to $150,000 for all outstanding public shares, to extend the period for completing its initial business combination.
NASDAQ
Aimei Health Technology Co., Ltd is holding an extraordinary general meeting to vote on amendments to its articles of association and trust agreement, as well as to ratify the appointment of its auditor.
NASDAQ
DEF 14A: Aimei Health Seeks Shareholder Approval to Amend Trust Agreement for Business Combination Extension
Aimei Health Technology Co., Ltd is seeking shareholder approval to amend its Investment Management Trust Agreement to reduce the required monthly extension fees, aiming to facilitate a business combination.